Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06224504
Other study ID # SBH-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2021
Est. completion date January 1, 2024

Study information

Verified date January 2024
Source Shanxi Bethune Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to assess the clinical effectiveness of combining Mindfulness-Based Stress Reduction (MBSR) with exercise intervention in improving anxiety, depression, sleep quality, and mood regulation in Chinese patients with non-small cell lung cancer (NSCLC).The control group received conventional psychological nursing care, while the intervention group received a combination of MBSR and exercise therapy. Pre- and post-treatment scores of anxiety, depression, sleep quality, and the BSRS-5 were compared.


Description:

To assess the clinical effectiveness of combining Mindfulness-Based Stress Reduction (MBSR) with exercise intervention in improving anxiety, depression, sleep quality, and mood regulation in Chinese patients with non-small cell lung cancer (NSCLC). A total of 60 lung cancer patients from a hospital in Shanxi Province were selected using convenience sampling and divided into an intervention group and a control group, with 30 patients in each group. The control group received conventional psychological nursing care, while the intervention group received a combination of MBSR and exercise therapy. The two group were evaluated by the questionnaire three times. One day before the intervention, the first questionnaire was conducted, and the basic data of the two groups of patients were collected. The second questionnaire evaluation of anxiety, depression, sleep quality, and the Brief Symptom Rating Scale (BSRS-5) was conducted 6 weeks after the end of the intervention, and the third questionnaire evaluation was conducted 8 weeks after the end of the intervention to evaluate the intervention effect of the two groups. Pre- and post-treatment scores of anxiety, depression, sleep quality, and the BSRS-5 were compared.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 1, 2024
Est. primary completion date January 1, 2022
Accepts healthy volunteers No
Gender All
Age group 44 Years to 65 Years
Eligibility Inclusion Criteria: - patients diagnosed with non-small cell lung cancer - patients aged between 20 and 74 years, without gender limitation - a score of 4-14 on the Short Symptom Rating Scale (BSRS-5) - a clinical prognosis of at least 6 months - clear consciousness, good functional ability, and unrestricted language communication - written informed consent provided by the patient Exclusion Criteria: - patients with severe physical illnesses or symptoms that impede learning and are considered life-threatening - patients with a BSRS-5 assessment score > 15 and suicidal ideation > 2 - patients unable to accurately describe their symptoms - patients with limited cooperation ability - patients who have previously undergone MBSR or other positive-thinking-focused psychotherapy methods

Study Design


Intervention

Behavioral:
routine health education
guided the diet of patients, and introduced the knowledge of the disease in detail
psychological nursing
hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
MBSR therapy
Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
exercise therapy
Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day

Locations

Country Name City State
China Combined Mindfulness-Based Stress Reduction and Exercise Intervention for Improving Psychological Well-being in Chinese Patients with Non-Small Cell Lung Cancer Taiyuan Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Shanxi Bethune Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary SAS score Self-Rating Anxiety Scale (SAS) one day before the intervention
Primary SAS score Self-Rating Anxiety Scale (SAS) at 6 weeks after the intervention
Primary SAS score Self-Rating Anxiety Scale (SAS) at 8 weeks after the intervention
Primary SDS score Self-Rating Depression Scale (SDS) one day before the intervention
Primary SDS score Self-Rating Depression Scale (SDS) at 6 weeks after the intervention
Primary SDS score Self-Rating Depression Scale (SDS) at 8 weeks after the intervention
Primary BSRS-5 score the five-item Brief Symptom Rating Scale (BSRS-5) one day before the intervention
Primary BSRS-5 score the five-item Brief Symptom Rating Scale (BSRS-5) at 6 weeks after the intervention
Primary BSRS-5 score the five-item Brief Symptom Rating Scale (BSRS-5) at 8 weeks after the intervention
Primary PSQI score Pittsburgh Sleep Quality Index (PSQI) one day before the intervention
Primary PSQI score Pittsburgh Sleep Quality Index (PSQI) at 6 weeks after the intervention
Primary PSQI score Pittsburgh Sleep Quality Index (PSQI) at 8 weeks after the intervention
See also
  Status Clinical Trial Phase
Terminated NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT05042375 - A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Phase 3
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Recruiting NCT05009836 - Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Recruiting NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT04054531 - Study of KN046 With Chemotherapy in First Line Advanced NSCLC Phase 2
Withdrawn NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Terminated NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01871805 - A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT05919641 - LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Completed NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma Phase 1